Welcome to our dedicated page for Materialise SEC filings (Ticker: MTLS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
When you track a technology innovator like Materialise, you need more than a PDF download. Investors typically start by asking where the Medical, Software, and Manufacturing numbers sit or how many new surgical guides cleared regulators. Our page gathers every disclosure—from the expansive annual report (Materialise annual report 10-K simplified) to each Materialise 8-K material events explained alert—so you can find answers fast.
Open a filing and Stock Titan’s AI highlights what matters: segment revenue shifts, R&D outlays tied to new 3D-printing materials, and risk updates on EU medical-device rules. Use our dashboards to follow Materialise insider trading Form 4 transactions; real-time alerts surface each Materialise Form 4 insider transactions real-time entry before markets react. Quarterly updates? The latest Materialise quarterly earnings report 10-Q filing arrives seconds after EDGAR posts, paired with concise Materialise earnings report filing analysis that decodes margins and backlog trends.
Need deeper context? Our AI Q&A engine excels at understanding Materialise SEC documents with AI, guiding you to the footnote that explains additive-manufacturing capacity or the table detailing geographic sales. Quickly review the Materialise proxy statement executive compensation to see how leadership pay aligns with growth, or examine any Materialise executive stock transactions Form 4 for insight into management sentiment. With real-time updates, AI-powered summaries, and coverage of every form, Materialise SEC filings explained simply becomes more than a promise—it’s your new workflow.
Materialise NV plans an additional listing of its ordinary shares on Euronext Brussels alongside its Nasdaq ADSs. The company stated that no shares will be offered and no capital will be raised in connection with the Brussels listing. The Board also approved an up to EUR 30 million ADS buyback over Nasdaq, subject to publication of shareholder authorization in the Belgian State Gazette and completion of the Brussels listing.
Materialise will hold an extraordinary general shareholders’ meeting on November 14, 2025 at 17:00 CET to consider share capital movements and buyback authorization, updates to the articles (including introducing double voting rights for certain shares), remuneration policy approval, appointing the statutory auditor for sustainability assurance, and confirming board composition. Admission to trading requires an FSMA-approved prospectus and is subject to market conditions, with no guarantee the listing will occur.
Materialise NV (MTLS) reported Q3 2025 results with total revenue of 66,259 kEUR, down 3.5% year over year. Net profit was 1,848 kEUR and the operating result was 2,522 kEUR.
Performance varied by segment: Medical grew 10.3% to 33,296 kEUR, while Manufacturing fell 17.1% to 22,677 kEUR and Software declined 7.4% to 10,286 kEUR. Gross margin held essentially steady at 56.8%. Adjusted EBITDA was 8,428 kEUR versus 9,895 kEUR, and Adjusted EBIT margin was 4.4% compared to 6.4% a year ago.
Operating cash flow was 10,359 kEUR and capital expenditures were 5,288 kEUR. Cash and cash equivalents were 132,022 kEUR at September 30, 2025, against gross debt of 64,278 kEUR, resulting in a net cash position of 67,744 kEUR. Basic EPS was 0.03.
MTLS Q2-25 6-K highlights: Revenue €64.8 m, -5.8 % YoY; Medical +16.7 %, Software -12.1 %, Manufacturing -24.9 %. Gross profit €37.8 m, margin 58.3 % (+130 bps). Operating profit €2.7 m vs €3.8 m; net profit €0.2 m (EPS €0.00) vs €3.9 m, hurt by €3.1 m FX loss.
Adjusted EBIT €3.1 m (-21 %), margin 4.7 % (-90 bps). Adjusted EBITDA €8.3 m (-10 %), margin 12.8 %. Medical remains growth engine: adj EBITDA €10.7 m, margin 32.7 % (+360 bps). Manufacturing swung to a €0.8 m loss; Software flat.
Opex trimmed 0.8 % YoY; Q2 operating cash flow swung to –€0.03 m from €8.4 m. Cash & equivalents rose to €116.7 m; gross debt €53.7 m (vs €41.3 m), leaving net cash €63.0 m (+€2.0 m). Equity stable at €249.5 m.
No guidance provided. Strong Medical momentum and liquidity are offset by revenue contraction, FX headwinds and Manufacturing weakness.
FAQ
What is the current stock price of Materialise (MTLS)?
What is the market cap of Materialise (MTLS)?
